Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
Why Shares of VectivBio Holding Are Up Today
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
VECT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of VectivBio Holding AG Is Fair to Shareholders
Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion
Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
VectivBio Announces Date of Extraordinary General Meeting of Shareholders
VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript
VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference
6 Underperforming IPO Stocks To Buy On The Dip
VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference
VectivBio Announces Closing of Comet Therapeutics Acquisition
VectivBio Announces Upcoming Investor Events
VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary
VectivBio Announces Results of Extraordinary General Meeting
VectivBio to Acquire Comet Therapeutics and Host R&D Day
VectivBio Publishes Invitation to the Extraordinary General Meeting
VectivBio Nominates Paul R. Carter and Murray W.
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients with Short Bowel Syndrome with Intestinal Failure
VectivBio Appoints Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
CORRECTION – VectivBio Announces Closing of $146.6 Million Initial Public Offering
VectivBio Announces Closing of $146.6 Million Initial Public Offering
US IPO Weekly Recap: The IPO Market Cools Off In A 2 IPO Week
Two Biotechs Are Set to Start Trading Today